37534-65-9

Usage

InChI:InChI=1/C10H12N2O3/c11-10(15)12-8(9(13)14)6-7-4-2-1-3-5-7/h1-5,8H,6H2,(H,13,14)(H3,11,12,15)

Upstream product

• 89-24-7 5-phenylimidazolidine-2,4-dione 
• 372-75-8 Citrulline 
• 150-30-1 Phenylalanine 
• 462-60-2 N-carbamoylglycine 
• 590-28-3 potassium cyanate 
• 57-13-6 urea 
• 7732-18-5 water 
• 119290-61-8 (±)‐phenylalanine benzyl ester p-toluenesulfonic acid 
• 63-91-2 L-phenylalanine 

Downstream Products

• 54896-72-9 (R)-3-phenyl-2-ureido-propionic acid 
• 949-45-1 (S)-3-phenyl-2-ureido-propionic acid 
• 3530-82-3 5-benzyl-hydantoin 
• 63-91-2 L-phenylalanine 
• 583-47-1 4-benzyl-oxazolidine-2,5-dione 
• 89-24-7 5-phenylimidazolidine-2,4-dione 

Relevant academic research and scientific papers

A practically simple, catalyst free and scalable synthesis of: N -substituted ureas in water

A practically simple, mild and efficient method is developed for the synthesis of N-substituted ureas by nucleophilic addition of amines to potassium isocyanate in water without organic co-solvent. Using this methodology, a variety of N-substituted ureas (mono-, di- and cyclic-) were synthesized in good to excellent yields with high chemical purity by applying simple filtration or routine extraction procedures avoiding silica gel purification. The developed methodology was also found to be suitable for gram scale synthesis of molecules having commercial application in large volumes. The identified reaction conditions were found to promote a unique substrate selectivity from a mixture of two amines.

N-(Hydroxyaminocarbonyl)phenylalanine: A novel class of inhibitor for carboxypeptidase A

N-(Hydroxyaminocarbonyl)phenylalanine (1) was designed rationally as a new type of inhibitor for carboxypeptidase A (CPA). The designed inhibitor was readily prepared from phenylalnine benzyl ester in two steps and evaluated to find that rac-1 inhibits CP

2-SUBSTITUTED-TRANS-5-ARYL-2,3,4,4a,5,9B-HEXAHYDRO-1H-PYRIDO[4,3-b]INDOLES

2-Substituted-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido 4,3-b!indoles of the formula (I): STR1 and the pharmaceutically-acceptable salts thereof, wherein the hydrogen atoms in the 4a position and 9b positions are in a trans relationship to each other and t